drugset / Trial / NCT07445815
A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
Timeline
- Start
- 2026-01-31
- Primary completion
- 2026-07-29
- Completion
- 2026-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Rabies Immunoglobulin (HRIG) | Protein / enzyme biologic | 20 iu/kg | Intramuscular |
| Subject | Rabies vaccine | Vaccine | — | Intramuscular |
| Subject | anti-rabies mAb | Monoclonal antibody | 40 iu/kg | Intramuscular |
| Subject | anti-rabies mAb | Monoclonal antibody | 80 iu/kg | Intramuscular |
Indications
No indication recorded.